Literature DB >> 15281019

Upregulation of lipogenic enzymes genes expression in white adipose tissue of rats with chronic renal failure is associated with higher level of sterol regulatory element binding protein-1.

Justyna Korczynska1, Ewa Stelmanska, Anna Nogalska, Marek Szolkiewicz, Elzbieta Goyke, Julian Swierczynski, Boleslaw Rutkowski.   

Abstract

Chronic renal failure (CRF) frequently results in hypertriglyceridemia and elevated plasma concentration of very-low-density lipoprotein (VLDL). These abnormalities are thought to be primarily due to depressed lipoprotein lipase and hepatic lipase activities, as well as impaired clearance of plasma lipoproteins. Some results suggest that not only lipoproteins catabolism but also their overproduction might contribute to hypertriglyceridemia in CRF. Because sterol regulatory element binding protein (SREBP) plays an important role in the regulation of lipid homeostasis, increased level of this transcription factor might be involved in modulating lipid metabolism in CRF. The purpose of the present study is to determine whether there is an altered regulation of the SREBP-1 in CRF rats and whether the altered regulation of SREBP-1 is associated with the upregulation of lipogenic enzymes genes expression in CRF rats. In the white adipose tissue (WAT) of CRF rats, marked increases in the microsomal (precursor) and nuclear (mature) forms of SREBP-1 have been found. The increase in SREBP-1 was associated with an increased level of lipogenic enzymes (acetyl-coenzyme A [CoA] carboxylase [ACC], adenosine triphosphate-citrate lyase [ACL], fatty acid synthase [FAS], glucose 6-phosphate dehydrogenase [G6PDH], 6-phosphogluconate dehydrogenase [6PGDH], and malic enzyme [ME]) genes expression. In turn, this was associated with an increased rate of fatty acids synthesis in WAT and a significant increase in plasma triacylglycerol (TAG) and VLDL concentration. Our study indicates that WAT SREBP-1 expression is increased in CRF rats and that SREBP-1 may play an important role in the increased fatty acid synthesis. These results reveal another facet of disturbed lipid metabolism in CRF. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15281019     DOI: 10.1016/j.metabol.2004.02.015

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  Disorders of lipid metabolism and chronic kidney disease in the elderly.

Authors:  Devasmita Choudhury; Meryem Tuncel; Moshe Levi
Journal:  Semin Nephrol       Date:  2009-11       Impact factor: 5.299

2.  Fatty acid synthase gene expression in human adipose tissue: association with obesity and type 2 diabetes.

Authors:  J Berndt; P Kovacs; K Ruschke; N Klöting; M Fasshauer; M R Schön; A Körner; M Stumvoll; M Blüher
Journal:  Diabetologia       Date:  2007-05-11       Impact factor: 10.122

3.  Serum fatty acid synthase as a marker of pancreatic neoplasia.

Authors:  Kim Walter; Seung-Mo Hong; Sinead Nyhan; Marcia Canto; Neal Fedarko; Alison Klein; Margaret Griffith; Noriyuki Omura; Susan Medghalchi; Frank Kuhajda; Michael Goggins
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-01       Impact factor: 4.254

4.  The decreased SIRT1 level may account for the lipid profile in chronic kidney disease.

Authors:  Gang Chen; Xuemei Li
Journal:  J Biol Res (Thessalon)       Date:  2019-10-16       Impact factor: 1.889

5.  Metabolic intervention on lipid synthesis converging pathways abrogates prostate cancer growth.

Authors:  V Fritz; Z Benfodda; C Henriquet; S Hure; J-P Cristol; F Michel; M-A Carbonneau; F Casas; L Fajas
Journal:  Oncogene       Date:  2012-12-03       Impact factor: 9.867

6.  Serum Endocannabinoid Levels in Patients With End-Stage Renal Disease.

Authors:  Hamid Moradi; Christina Park; Miki Igarashi; Elani Streja; Donovan A Argueta; Melissa Soohoo; Jennifer Daglian; Amy S You; Connie M Rhee; Moti L Kashyap; Nicholas V DiPatrizio; Nosratola D Vaziri; Kamyar Kalantar-Zadeh; Daniele Piomelli
Journal:  J Endocr Soc       Date:  2019-08-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.